A randomized, multi-center, phase 2 study of ivaltinostat (Ival) plus capecitabine (Cape) versus capecitabine alone in the maintenance setting in patients with metastatic pancreatic adenocarcinoma (mPDAC)

被引：0
|
作者：
Fountzilas, Christos
Ko, Andrew H.
Borazanci, Erkut Hasan
D'Olimpio, James Thomas
Hecht, J. Randolph
Tang, Shou-Ching
Shields, Anthony F.
Salkeni, Mohamad Adham
Michelson, Glenn
Cho, Gene
Liganor, Lorna
Cho, Sangsook Ahn
Walker, Evan Justin
机构：
[1] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[2] Univ Calif San Francisco, Helen Diller Family Comprehens, San Francisco, CA USA
[3] HonorHealth Res Inst, Scottsdale, AZ USA
[4] Clin Res Alliance, Westbury, NY USA
[5] UCLA, Jonsson Comprehens Canc Ctr, Santa Monica, CA USA
[6] LSU Sch Med, New Orleans, LA USA
[7] Karmanos Canc Inst, Detroit, MI USA
[8] Virginia Canc Specialists VCS Res Inst, Fairfax, VA USA
[9] CG Pharmaceut Inc, Orinda, CA USA
[10] Univ Calif San Francisco, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4206
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Biomarker Analysis of the Phase III NALA Study of Neratinib plus Capecitabine versus Lapatinib plus Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
    Saura, Cristina
    Matito, Judit
    Oliveira, Mafalda
    Wildiers, Hans
    Brufksy, Adam M.
    Waters, Simon H.
    Hurvitz, Sara A.
    Moy, Beverly
    Kim, Sung-Bae
    Gradishar, William J.
    Queiroz, Geraldo Silva
    Cronemberger, Eduardo
    Wallweber, Gerald J.
    Bebchuk, Judith
    Keyvanjah, Kiana
    Lalani, Alshad S.
    Bryce, Richard
    Vivancos, Ana
    Eli, Lisa D.
    Delaloge, Suzette
    CLINICAL CANCER RESEARCH, 2021, 27 (21) : 5818 - 5827
  • [22] Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer
    Yu Hong Li
    Hui Yan Luo
    Feng Hua Wang
    Zhi Qiang Wang
    Miao Zhen Qiu
    Yan Xia Shi
    Xiao Juan Xiang
    Xiao Qing Chen
    You Jian He
    Rui Hua Xu
    Journal of Cancer Research and Clinical Oncology, 2010, 136 : 503 - 510
  • [23] Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer
    Li, Yu Hong
    Luo, Hui Yan
    Wang, Feng Hua
    Wang, Zhi Qiang
    Qiu, Miao Zhen
    Shi, Yan Xia
    Xiang, Xiao Juan
    Chen, Xiao Qing
    He, You Jian
    Xu, Rui Hua
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (04) : 503 - 510
  • [24] A phase I/II study combining tosedostat with capecitabine in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
    Wang-Gillam, Andrea
    Du, Lingling
    Teague, Andrea S.
    Suresh, Rama
    Lim, Kian-Huat
    Amin, Manik A.
    Pedersen, Katrina
    Tan, Benjamin R.
    Huffman, Jess
    Lockhart, Albert C.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [25] A Randomized Phase III Study of Patients With Advanced Gastric Adenocarcinoma Without Progression After Six Cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical Observation
    Lee, Guk Jin
    Kim, Hyunho
    Cho, Sung Shim
    Park, Hyung Soon
    An, Ho Jung
    Woo, In Sook
    Byun, Jae Ho
    Hong, Ji Hyung
    Ko, Yoon Ho
    Sun, Der Sheng
    Won, Hye Sung
    Jin, Jong Youl
    Park, Ji Chan
    Kim, In-Ho
    Roh, Sang Young
    Shim, Byoung Yong
    JOURNAL OF GASTRIC CANCER, 2023, 23 (02) : 315 - 327
  • [26] Fruquintinib plus capecitabine versus capecitabine as first-line maintenance treatment of metastatic colorectal cancer (mCRC): Update results from the randomized, controlled, phase Ib/II study
    Li, Wenhua
    Chang, Jinjia
    Wang, Chenchen
    Peng, Junjie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Comparison of efficacy of aspirin plus epirubicin, oxaliplatin, and capecitabine versus epirubicin, oxaliplatin, and capecitabine alone in patients with locally advanced and metastatic gastric cancer: A randomized clinical trial
    Jafa, Esha
    Dubashi, Biswajit
    Kayal, Smita
    Kate, Vikram
    Ganesh, Rajesh Nachiappa
    Sunitha, V. C.
    Charles, L.
    Nisha, Yadav
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [28] AN INTERIM ANALYSIS OF A PHASE II, OPEN-LABLE, MULTI-CENTER, PROSPECTIVE STUDY OF PACLITAXEL PLUS CAPECITABINE WITH SUBSEQUENT CAPECITABINE MAINTENANCE AS FIRST-LINE TREATMENT IN ADVANCED GASTRIC CANCER
    Zhang, X.
    Shen, L.
    Gong, J.
    Hu, B.
    Zhang, F.
    Zhang, J.
    Xu, N.
    Fan, Q.
    Bai, Y.
    ANNALS OF ONCOLOGY, 2010, 21 : 227 - 227
  • [29] A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab
    Xu, Binghe
    Ma, Fei
    Ouyang, Quchang
    Li, Wei
    Jiang, Zefei
    Tong, Zhongsheng
    Liu, Yunjiang
    Li, Huiping
    Yu, Shiying
    Feng, Jifeng
    Wang, Shusen
    Hu, Xichun
    Zhu, Xiaoyu
    Zou, Jianjun
    CANCER RESEARCH, 2018, 78 (04)
  • [30] Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
    Cunningham, David
    Lang, Istvan
    Marcuello, Eugenio
    Lorusso, Vito
    Ocvirk, Janja
    Shin, Dong Bok
    Jonker, Derek
    Osborne, Stuart
    Andre, Niko
    Waterkamp, Daniel
    Saunders, Mark P.
    LANCET ONCOLOGY, 2013, 14 (11): : 1077 - 1085
12345